CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 6, 2019--
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 4:15pm ET at the Parker New York in New York, NY.
A webcast of the presentation will be available in the investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 trial, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190806005106/en/
Source: Catabasis Pharmaceuticals, Inc.
Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971